EP2438863A1 - Système et procédés pour analyser les durées des temps de pause dans la parole - Google Patents

Système et procédés pour analyser les durées des temps de pause dans la parole Download PDF

Info

Publication number
EP2438863A1
EP2438863A1 EP10186624A EP10186624A EP2438863A1 EP 2438863 A1 EP2438863 A1 EP 2438863A1 EP 10186624 A EP10186624 A EP 10186624A EP 10186624 A EP10186624 A EP 10186624A EP 2438863 A1 EP2438863 A1 EP 2438863A1
Authority
EP
European Patent Office
Prior art keywords
brain
subject
speech
pause time
individual
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP10186624A
Other languages
German (de)
English (en)
Inventor
Catarina Erikson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Phibio Science AB
Original Assignee
Phibio Science AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phibio Science AB filed Critical Phibio Science AB
Priority to EP10186624A priority Critical patent/EP2438863A1/fr
Priority to PCT/EP2011/067385 priority patent/WO2012045774A1/fr
Publication of EP2438863A1 publication Critical patent/EP2438863A1/fr
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4803—Speech analysis specially adapted for diagnostic purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/40—Detecting, measuring or recording for evaluating the nervous system
    • A61B5/4058—Detecting, measuring or recording for evaluating the nervous system for evaluating the central nervous system
    • A61B5/4064—Evaluating the brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/16—Devices for psychotechnics; Testing reaction times ; Devices for evaluating the psychological state
    • A61B5/168—Evaluating attention deficit, hyperactivity
    • G—PHYSICS
    • G10—MUSICAL INSTRUMENTS; ACOUSTICS
    • G10L—SPEECH ANALYSIS TECHNIQUES OR SPEECH SYNTHESIS; SPEECH RECOGNITION; SPEECH OR VOICE PROCESSING TECHNIQUES; SPEECH OR AUDIO CODING OR DECODING
    • G10L25/00—Speech or voice analysis techniques not restricted to a single one of groups G10L15/00 - G10L21/00
    • G10L25/78—Detection of presence or absence of voice signals
    • G10L2025/783—Detection of presence or absence of voice signals based on threshold decision

Definitions

  • This invention pertains to the field of systems and methods for assessment of an attentional lap (pause time) induced by brain dysfunction which is of developmental origin of the central nervous system (CNS) in children, adolescents and adults, or reflects the aging and disease processes of the CNS in the elderly. More particularly the invention relates to such systems and methods for determining or diagnosing if the person suffers from attentional lapses induced by brain dysfunction or is in risk thereof by analyzing the speech of the person.
  • a person's ability to concentrate and to focus on external stimuli may be compromised by disturbances in the developmental trajectories of the CNS, by fatigue or intoxication, or by changes in CNS induced by aging processes or age related diseases.
  • CNS developmental trajectories of the CNS
  • fatigue or intoxication or by changes in CNS induced by aging processes or age related diseases.
  • increasing evidence has accumulated that different systems and subsystems in the brain are responsible for such behavioural difficulties.
  • Particular interest has been drawn to the functional correlations and the coherence of activity of widespread neuronal populations which are observed during a resting state (default mode network, DMN) and subsystems of the DMN which are believed to participate during goal-directed activity (task positive network) or not (task negative network).
  • the low frequency coherent neuronal oscillations of the DMN are deactivated which allows the activation of task positive networks to perform the task.
  • the activity of the brain constantly shifts between states of internal tasks such as daydreaming, self-reference, envision of the future, retrieving memories and so on, and functional activation of DMN-opposed (anti correlated) subsystems needed to process and to react to external information, thus neglecting internal tasks.
  • This constant switch between "on” and “off' between different states of the brain may be compromised and such compromise can result in suboptimal performance by the person.
  • One of the behavioural manifestations of such compromise is attentional difficulties in a subject, believed to be due to an imbalance in the strength of neuronal coherence between systems.
  • ADHD Attention Deficit Hyperactivity Disorder
  • ADD Attention Deficit Disorder
  • Attentional fluctuations have commonly been assessed by continuous performance tests such as reaction time tasks. Such tasks are externally driven such that visual or auditory stimuli are presented and the subjects need to react to these stimuli by for example press a button in response to the stimulus. These tasks engage the so called external loop of the brain.
  • This reflexive view of brain function has traditionally been very informative but does not consider the intrinsic capacity of the brain's own ability to switch "on” and “off' between different modes of behaviour, and does not reflect the speed of the so called internal loop of the brain, i.e. the intrinsically generated higher order cognitive processing.
  • a compromise of the self-paced speed of intrinsic brain processing to open-ended external information may in fact be one of the earliest behavioural consequences of brain dysfunction, which can be characterized by moment-to-moment attentional fluctuations.
  • the brain may be damaged in many various ways by the aging CNS, and CNS-changes may precede clinical evidence of such changes for many decades. This can be seen for example in mild cognitive impairment (MCI), small or large vessel diseases, damage of the blood brain barrier function, atherosclerosis, etc. where clinical symptoms of ongoing brain damaging processes may not be evident until a certain point is reached in the development of such processes.
  • MCI mild cognitive impairment
  • small or large vessel diseases damage of the blood brain barrier function
  • atherosclerosis etc. where clinical symptoms of ongoing brain damaging processes may not be evident until a certain point is reached in the development of such processes.
  • AD Alzheimer's disease
  • MS Multiple sclerosis
  • Dementia and dementia-associated diseases are actually ranked as the fourth common cause of death in industrialized civilizations of the globe, after cardiac diseases, cancer, and stroke. In Sweden alone, having a population of only nine million, about 150000 - 200.000 persons are suffering from dementia. About 7 percent of the elderly and 20-30 percent of the 85 year old persons suffer from dementia. As the percentage of elderly of the total population will increase due to longer expected life, the absolute number of patients will even increase with time. Therefore, there is a need to identify persons at risk of developing dementia or having a certain degree of dementia as early as possible in order to be able to provide suitable treatment.
  • ADHD attention deficit hyperactivity disorder
  • a dementia testing apparatus e.g. for senile dementia, which has a test chart that comprises tale including test sentences containing colored words and questions for determining whether words are colored with a color expressed by a colored word.
  • an answer obtaining section of the apparatus obtains answers from a patient that are made within predetermined answer time limits to a first and a second examination chart.
  • the first examination chart has inspection sentences where a character group constituting a story including color words each representing color is tinted with plural colors such that individual color word has characters of the same color, requires a determination as to whether the color of characters constituting the color word is the same color as color represented by the color word.
  • the second examination chart has a combination of questions concerning contents of the inspection sentences and answers which are prepared for each question and one of which is to be selected.
  • a dementia degree inspection section of the apparatus a dementia degree of the subject based on the answers obtained by the answer obtaining section is determined.
  • a dementia test apparatus comprising an answer obtaining section for obtaining an answer of a subject to both a dementia degree test chart which requires the subject to exercise a plurality of judgments at the same time and obtain an answer in such a form that correction of judgment is objectively determined, and a dementia factor degree test chart comprising a combination of multiple questions concerning sensibility and a multiplicity of answers alternatively selected from questions prepared for each of the former questions, and a dementia degree test section for testing a dementia degree indicative of the current degree of dementia of the subject based on an answer obtained by the answer obtaining section, and for estimating a future dementia degree of the subject.
  • test systems of the prior art suffer from the same drawbacks as manually performed cognitive tests, e.g. a dependency of the test on educational, social and cultural factors, including language, of the subject.
  • WO 2009/056650 discloses a system for assessment of brain disease induced brain dysfunction based on the accumulated pause time of speech over a period of time. Individual variations in brain function of subjects throughout a period may not be detected, and/or the reliability and/or sensitivity for detecting brain dysfunction may not be sufficient in such method.
  • an improved system and/or method e.g. for assessing neurodevelopmental disorders or brain dysfunction caused by diseases of the aging brain or a risk for developing such brain dysfunction, would be advantageous and in particular a system and/or method allowing for increased flexibility, cost-effectiveness, patient comfort and/or independency of educational background and/or cultural factors and language of a subject to be tested, would be advantageous.
  • embodiments of the present invention preferably seek to mitigate, alleviate or eliminate one or more deficiencies, disadvantages or issues in the art, such as the above-identified, singly or in any combination by providing a system, a method, a computer program, and a medical workstation according to the appended patent claims.
  • Random speech is registered and analyzed. Correlations between an accumulated pause time in relation to the total speech time and brain dysfunction are analyzed.
  • a system comprising the system is devised for assessment of the brain functional status of a subject, and wherein the brain functional status comprises a neurodevelopmental disorder or a brain disease.
  • the system is adapted to determine an occurrence and/or stage of the neurodevelopmental disorder or brain disease induced brain dysfunction in the subject.
  • the system comprises an apparatus that is adapted to determine the occurrence and/or stage of the neurodevelopmental disorder or brain disease induced brain damage in the subject from speech of the subject.
  • the speech may be random speech of the subject. Alternatively, or in addition, the speech may be based on a naming task, which is arranged and performed independent of the subject's language.
  • the apparatus comprises units that are operatively connected to each other, which comprises a unit for registering the speech of the subject over a period of time; a processing unit devised for analyzing the registered speech and configured to determine a plurality of individual pause time components of the speech and being adapted to determine a statistical distribution of said plurality of individual pause time components; and a processing unit that is adapted to determine the occurrence and/or stage of the brain disease induced brain damage from the statistical distribution.
  • a method for assessment of a brain status of a subject comprising analyzing speech of the subject and determining aforementioned plurality of individual pause time components of the speech; determining a statistical distribution of said plurality of individual pause time components; and determining an occurrence and/or stage of the neurodevelopmental disorder or brain dysfunction induced by the brain disease in the subject based on the statistical distribution.
  • a computer program for processing by a computer is provided.
  • the computer is preferably the one or both of said aforementioned processing units.
  • the computer program is configured for assessment of a brain status of a subject, wherein the brain status comprises a neurodevelopmental disorder or brain dysfunction induced by a brain disease.
  • the computer program comprises a first code segment for analyzing speech of the subject and determining a plurality of individual pause time durations of the speech as defined herein; and a second code segment for determining statistical distribution of said plurality of individual pause time components; and a third code segment for determining an occurrence and/or stage of the brain dysfunction due to a neurodevelopmental disorder or brain dysfunction induced by brain disease in the subject based on this statistical distribution.
  • Embodiments of the invention do not comprise cognitive content questions, and thus the above mentioned drawbacks related thereto are avoided.
  • naming tests are performed in embodiments, these are provided content-independent.
  • Diseases or conditions to be diagnosed by embodiments of the invention comprise any structural or functional disruption of the brain architecture, including neurodevelopmental disorders or disorders associated with the normal aging process, or associated with any brain disorder of cortical neurodegenerative or brain white matter origin. Furthermore, this includes any induction of inflammatory processes affecting the blood-brain barrier functions of the brain microvascular system, including any genetic risk factors or genetic polymorphisms associated with these processes.
  • MS Multiple sclerosis
  • VaD cerebrovascular disease
  • MCI mild cognitive impairment
  • FTD/FLD fronto-temporal dementia
  • LBD/DLB dementia with Lewy body disease
  • PD Parkinson's disease
  • Conditions such as ADHD may sometimes be difficult to clinically diagnose due to comorbidity of other conditions, but embodiments of the invention can aid in the diagnosis.
  • One of the most evident clinical characteristics of ADHD is frequent laps in the ability to maintain attention over time.
  • Previous research has seldom described the intra-individual moment-to-moment attentional variations which are typical for ADHD. This variability is previously typically described in terms of mean value analysis and different measures for deviations, for example standard deviations.
  • Patients with ADHD often have significantly larger mean values and a larger variation in their performance compared to healthy control individuals of the same age. Such analysis is however not sufficient as such methods do not reveal the individual variations over time (milliseconds and seconds).
  • reaction time tests which essentially measure the ability of the motor systems of the brain to quickly react on an external stimulus, i.e. the so called “outer loop" of the brain function.
  • a subject should press a button as quickly as possible upon the presentation of a visual or auditory stimuli.
  • those which require a higher degree of mental processing of stimuli i.e. those tasks which require the activation of the subjects "inner loop” of brain function, i.e. the brains ability to produce its own response in its own pace.
  • This distinction of the brains reflex function in contrast to the self-acting ability of thinking leads to two entirely different aspects of the brains function.
  • Language in the context of the present application is to be understood as a system for expression of thoughts, feelings etc. by use of a burst of spoken sounds.
  • the use of such a system is a distinguishing characteristic of man compared with other animals. Different nations or people use different languages, e.g. French, Chinese, etc. Two or more individuals speaking the same language can communicate with each other via that system.
  • Language in the context of the present application does expressly not include other systematic or nonsystematic means of communicating, such as gestures or animal sounds.
  • Speech in the context of the present application is to be understood as the act of speaking, i.e. an utterance of the above mentioned spoken words, independent of a language. Speech in the context of the present application does expressly not include the meaning of national or regional language or dialect. Lungs and vocal cords produce basic sounds that result in speech being produced in a manner of articulation determined how tongue, lips, and other speech organs are involved in making a sound make contact. Speech also comprises pause components of silence or absence of sounds, e.g. between words or sentences.
  • the speed of the brains own ability of thinking may be studied by measuring the length of the pause times that are occurring when a subject is required to name a series of simple, colored figures. This has been described in patent application PCT/SE2010/050480 , and published patent application WO 2009/056650 , which are incorporated herein by reference in their entirety for all purposes. In the aforementioned patent applications the total pause time has been analyzed, and it has been shown that the longer the total pause time is for completing the task, the slower the process of thinking required for completing the task. This is true for both young people with ADHD and for patients with Alzheimer's decease.
  • a slow process of thinking may be due to difficulties for the individual to maintain attention, and variations in the attention of an individual are common symptoms at ADHD. Difficulties to maintain attention is also occurring at Alzheimer's decease. A variation in the attention is defined as a pause time (time of hesitation) that exceeds a normal threshold value (+/- a standard deviation).
  • Aforementioned WO 2009/056650 discloses a system for assessment of brain disease induced brain dysfunction based on the accumulated pause time of speech over a period of time. Individual variations in brain function of subjects throughout a period may not be detected, e.g. as pause time frequency is discarded, and/or the reliability and/or sensitivity for detecting brain dysfunction may not be sufficient in such method.
  • Determination of a statistical distribution of a plurality of individual pause time components has not previously been disclosed. This has the advantage that the individual variations may be resolved, throughout the testing period, which has previously been unresolved in the mean value analysis.
  • the occurrence and/or stage of said brain disease induced brain dysfunction from the statistical distribution such as a chronological distribution of the individual pause times during a test, may accordingly be determined.
  • Information previously discarded, e.g. when the pause times occur, and how their length and occurrence (frequency) varies over time, may now be used to characterize the brain function in more detail. The reliability is improved as abnormal deviations throughout the test period may be resolved and investigated. Measuring errors may thus also be detected.
  • a tendency of a deficiency in a subject's brain function may be detected, at an earlier stage, as the peaks of the individual pause times are resolved in the pause time spectra, in contrast to a previous situation where this information was discarded in the accumulated pause time.
  • the threshold for detecting a change in brain function is thereby lowered, i.e. the sensitivity of the method is increased, and suitable treatment may be introduced at an earlier stage.
  • the parameters in the pause time spectra such as the individual length and occurrence (frequency) of the pauses may advantageously be used for determining the effects of medical treatment of ADHD or dementia.
  • the effect of such treatment on these parameters is previously unknown.
  • these parameters may be used to differentiate patients with ADHD and other neurodevelopmental disabilities, e.g. global learning disability or mental retardation, or neurological disorders such as epilepsy, brain tumors etc. The effect of such conditions on the aforementioned parameters is previously unknown.
  • the total length of speech is not predefined. This provides for a patient-convenient testing environment without stress. There is no pre-defined time limit for a certain naming task for which the plurality of individual pause times are determined, for assessing a statistical distribution of the plurality of individual pause times. Rather the task is fixed, but not the time for the task. All voice information from an entire measurement period is made use of. Measurement time starts e.g. when stimuli are presented and stopped when the subject so indicates, e.g. by pressing a stop button when a naming task is finished or the subject aborts the speech registration of other reasons (e.g. tired).
  • a method for assessment of a functional brain status of a subject is now described; wherein the functional brain status comprises a neurodevelopmental disorder or a brain disease.
  • the method comprises analyzing speech of the subject and determining a plurality of individual pause components of the speech; determining a statistical distribution of the plurality of individual pause time components; and determining an occurrence and/or stage of the neurodevelopmental disorder or the brain disease in the subject based on the statistical distribution.
  • the pause component, absence of sound is a key component of the present invention.
  • the method 100 comprises a number of steps 101-104.
  • a statistical distribution of the individual pause times is determined for the stimulus set.
  • the distribution may be imposed on a range of normal reference or threshold values for a diagnosis.
  • a threshold value may be defined as a number of individual pause times exceeding a threshold duration for a pause time.
  • Non-overlapping pause times of the statistical distribution compared to a range of reference values may be detected for immediate indications of abnormal deviations in a temporally resolved manner.
  • the pause time durations are obtained between all of the vocal bursts recorded during the overt naming of a randomly generated order and a random order of any number of combinations of different colors and different shapes, e.g. four colors and four shapes.
  • One example of a randomly generated set of stimuli 700 is presented in Fig. 4 , and one excerpt of a recorded time series showing examples of pause durations, is shown in Fig. 3 .
  • random speech may be registered and analyzed in other embodiments.
  • the durations (milliseconds) and the statistical distribution of individual pause times are analyzed for a diagnosis of presence or absence of brain dysfunction.
  • naming errors are not automatically recorded. The reason for this is that naming errors (misnaming of the stimulus, change of naming order) not significantly contribute to the total naming time.
  • pause time includes the inter-word pause times between vocal bursts of overt articulation.
  • Information processing speed i.e. mental speed
  • pause time i.e. one and the same tests (for example Digit Symbol, or Stroop Color-Word test, Trail making test, etc.) is interpreted as measuring mental speed in one study, while in other studies the same test is assumed to measure mental flexibility. This is a frequently occurring issue of definition and face validity of test instruments.
  • Reaction time is often used as a measure of psychomotor speed or processing speed.
  • processing speed comprising decision speed, perceptual speed, psychomotor speed, reaction time, and psychophysical speed.
  • Empirical evidence shows that articulation and pause time are two separate components of the mental processes subserving serial naming tasks, and these two components are not correlated with each other when a verbal response is measured.
  • an apparatus to perform the above describe method comprise a computer having one or more processing units, a microphone, and a speech analysis system. These components may be incorporated into a hand-held computer device which is easy to use, and which calculates the duration of individual pauses as they occur in chronological order of presentation. Alternatively, a medical workstation may be used for performing the test.
  • Analyzed parameters may be automatically compared with age-matched normal ranges of reference values.
  • Such an apparatus is provided in a system that is devised for assessment of a brain status of a subject, and wherein the brain status comprises a neurodevelopmental disorder or the risk for and/or the presence of a brain disease induced brain dysfunction.
  • the system is adapted to determine an occurrence and/or stage of the brain dysfunction of neurodevelopmental origin or induced by the brain disease in the subject.
  • the system comprises an apparatus that is adapted to determine the occurrence and/or presence of the neurodevelopmental disorder or brain dysfunction induced by the brain disease in the subject from the plurality of individual pause durations between speech sounds produced by the subject.
  • the apparatus comprises units that are operatively connected to each other, which comprises a unit for registering the speech of the subject over a period of time; a processing unit devised for analyzing the registered speech and configured to determine a plurality of individual pause component of the speech and determine a statistical distribution of said plurality of individual pause time components; and a processing unit that is adapted to determine the occurrence and/or stage of the brain dysfunction of neurodevelopmental origin or induced by the brain disease from the statistical distribution.
  • Fig. 2 is a schematic illustration of an embodiment of such an apparatus 200 and Fig. 3 is a graph 300 showing an excerpt from a registered speech signal 310 of a subject, with several pauses between vocal bursts.
  • Apparatus 200 comprises a microphone 201 for registering speech of a subject.
  • the microphone 201 may be any known microphone suitable for registering voice signals and converting these to electrical signals for further processing in the apparatus 200.
  • the microphone 201 is compatible with subsequent processing units, such as Digital Signal Processing (DSP) units, Analog Digital (A/D) converters, processing units, etc.
  • Unit 202 may digitize the signal from the microphone 201 and/or apply a gain control.
  • the converted and/or adjusted signal is then provided to a processing unit 204, which may be a control and sound processing unit.
  • Units 202 and 204 may be provided as a DSP subsystem that is commercially available.
  • the DSP system communicates with an analyzing unit 206.
  • DSP system 206 may also comprise a memory 207 for, at least temporary, storing or recording the registered speech.
  • the analyzing unit 206 may determine a plurality of individual pause time components of the speech, e.g. from a stored speech signal.
  • a sound signal 310 corresponding to the vocal bursts of speech of a subject, comprises two exemplary words uttered by the subject between times t1 and t2, as well as between times t3 and t4.
  • a pause time is given between times t2 and t3.
  • the analyzing unit 206 may determine a statistical distribution of the individual pause times from the speech. Another unit, or analyzing unit 206, is adapted to determine the occurrence and/or stage of said neurodevelopmental disorder or brain disease induced brain dysfunction from the statistical distribution of individual pause times. The distribution may accordingly be indicative of any abnormal pause time values associated with any event during recording of the speech signal. Abnormalities or indications of deviations may be automatically detected by analyzing unit 206. Abnormalities may also include deficiencies in the equipment used for registering the speech data, and/or any brain function, thereby increasing the reliability of the system. The distribution of individual pause times allows for continuous monitoring or subsequent follow-up of any isolated or reoccurring abnormalities. The statistical distribution may be a chronological distribution of the plurality of individual pause time components.
  • the unit 206 may compare the plurality of individual pause time components of the registered speech with pause time component threshold values to determine the occurrence and/or stage of the neurodevelopmental disorder or brain disease induced brain dysfunction.
  • the pause time component threshold values may comprise different criteria that may be input to the system.
  • the threshold values may comprise a predefined number of the plurality of individual pause times exceeding a pause time threshold or limit duration. For example, if the number of individual pause times exceeding a duration of 1000 ms is amounting to 3 individual pause times, the unit 206 may determine that a abnormal deviation has occurred, which may be indicative of brain dysfunction. Further, an increase or decrease of abnormal deviations may be indicative of a medication.
  • the pause time threshold duration is may be predefined threshold duration outside of +/- one standard deviation of a reference pause time of a healthy subject.
  • the reference pause time may be a range of reference pause times of a healthy population, and the unit 206 may compare the values of pause times in the reference range with the statistical distribution of individual pause times for determining overlapping or non-overlapping values for determining the occurrence and/or stage of said neurodevelopmental disorder or brain disease induced brain dysfunction.
  • the range of normal reference or threshold values stored in memory 207 for a diagnosis. Hence, non-overlapping pause times of the statistical distribution compared to a range of reference values may be detected for immediate indications of abnormal deviations in a temporally resolved manner.
  • the apparatus 200 further comprises a human user interface for showing the results of the test and communicating with the user.
  • the hand-held device may in addition comprise an internal microphone or capability for a microphone which may be connected by wire or wire-less, e.g. by Blue Tooth, IR or any other transmission means.
  • Some of the embodiments may be a software implementation to be executed on a workstation, e.g. computer, laptop. Moreover, some embodiments may additionally comprise a hardware integrated chip with the system integrated to be connected to the workstation, computer or laptop.
  • the analyzing unit 206 may be comprised in other processing units of the apparatus. Likewise memory 207 may be part of other memory units of the apparatus.
  • USB dongle Universal serial bus
  • workstation computer or laptop from which the system is executed as a software code or to unlock the system.
  • Fig. 4 is an illustration of some examples of color and shape combinations, i.e. sets of stimuli, of a cognitive test for the assessment in the method.
  • a stimuli may comprise a sequence of individual visual and/or auditive stimuli in time for naming by the subject.
  • a full set of stimuli may be presented to the subject at one time, whereupon the subject should name the full set as quickly as possible.
  • a visual set of stimuli is shown, comprising four different shapes.
  • the shapes may have any of four different colors (e.g. black, red, yellow, blue).
  • the method uses either a larger predefined set of such combinations or an undefined set of such combinations, all of which may be randomly generated and randomly ordered by the method.
  • Such a chart may be provided virtually via a user interface, e.g. of a medical workstation, to the subject to be tested.
  • the medical workstation comprises the usual computer components like a central processing unit (CPU), memory, interfaces, etc. Moreover, it is equipped with appropriate software for processing sound data received from sound data input sources, such as data obtained from microphone devices.
  • a computer program for processing by a computer is provided is some embodiments.
  • the computer program is configured for assessment of a brain status of a subject, wherein the brain status comprises a neurodevelopmental disorder or a brain dysfunction induced by a brain disease.
  • the computer program comprises a first code segment for analyzing speech of the subject and determining a plurality of individual pause component of the speech; a second code segment for determining a statistical distribution of said plurality of individual pause time components; and a third code segment for determining an occurrence and/or stage of the brain damage induced by brain disease in the subject based on the statistical distribution.
  • the computer program may for instance be stored on a computer readable medium, accessible by the medical workstation.
  • the medical workstation may further comprise a monitor, for instance for the display of rendered visualizations, as well as suitable human interface devices, like a keyboard, mouse, etc., e.g. for interacting with the medical workstation.
  • the medical workstation may be part of a system.
  • the medical workstation may also provide data for suggesting treatments based on the assessment outcome.
  • the medical workstation may have a graphical user interface for computer-based assessment of brain damage induces brain dysfunctions.
  • the graphical user interface may comprise components for visualizing the methods described above in this specification or recited in the attached claims.
  • Embodiments of the system or apparatus described herein may advantageously be implemented and used for carrying out a method, such as the above described or the following method.
  • a method for assessment of a brain status of a subject wherein the brain status comprises a neurodevelopmental disorder or a brain disease induced brain dysfunction
  • the method comprises analyzing speech of the subject and determining a plurality of individual pause components of the speech, as defined herein; determining a statistical distribution of said plurality of individual pause time components; and determining an occurrence and/or stage of the neurodevelopmental disorder or brain disease induced brain dysfunction in the subject based on the statistical distribution.
  • the method may comprise registering the speech and/or recording the speech of the subject over a period of time; and wherein the analysis of the speech comprises the analysis of the registered speech and/or the recorded speech for determining the length of the pause component between vocal bursts of the speech.
  • the analyzing the overt speech of the subject may be performed irrespective of a language of the speech.
  • the assessment may be a cognitive test based assessment, comprising the subject freely defining parameters of the cognitive test.
  • the method may comprise providing a basis for medical personal for deciding if a subject has signs of a neurodevelopmental disorder or a brain disease induced brain dysfunction or not.
  • the method may comprise directing primary health care resources to those subjects who are at high risk for having a brain disease induced brain dysfunction, and who need further assessment for their diagnosis, while saving financial costs for unnecessary evaluations of patients with negative test results.
  • the method may comprise basing the occurrence and/or stage of the neurodevelopmental disorder or the brain disease induced brain dysfunction on a threshold value of the individual pause time components.
  • the method may further comprise determining the occurrence and/or stage of the neurodevelopmental disorder or the brain disease induced brain dysfunction by comparing the duration of the individual pause times with normal reference values.
  • the method wherein the determining of the occurrence and/or stage of the neurodevelopmental disorder or the brain disease induced brain dysfunction from the individual pause components may comprise associating an increase in individual pause times with white matter function/dysfunction and/or cerebrovascular dysfunction, in either healthy aging, mild cognitive impairment (MCI) or dementia.
  • MCI mild cognitive impairment
  • the assessment may be cognitive test based assessment, wherein the subject is free to define parameters of the cognitive test, wherein the cognitive test provides measures of processing speed, such as for example using simple colors and shapes, or naming other defined stimuli, and is non-invasive.
  • the method wherein the cognitive test may be implemented in an education and culture-free manner, and wherein the cognitive test does not comprise questions related to knowledge of the subject.
  • the brain disease induced brain dysfunction may be of developmental origin of the central nervous system (CNS), or reflect the aging and disease processes of the CNS in the elderly.
  • CNS central nervous system
  • the neurodelvelopmental disorders may be related to ADHD, autism spectrum disorders, global learning deficits or mental retardation, or comorbid disorders of neurological origin (e.g. brain tumour, epilepsy etc.) while brain disease induced brain dysfunction may be related to dementia, such as Alzheimer's disease; Multiple sclerosis (MS); Parkinson's disease (PD); dementia with Lewy bodies (DLB/LDB); Amytrophic Lateral Sclerosis (ALS); subcortical white matter disease or demyelinating disease; HIV; malaria; cerebrovascular disease (VaD); encephalitis; traumatic brain injury (TBI); mild cognitive impairment (MCI); traumatic brain injury (TBI); effects of street drugs; alcohol abuse; side effects of prescribed drugs and/or pharmaceutical drug treatments; and diseases of other bodily organs such as heart, liver, lung or otherwise.
  • MS Multiple sclerosis
  • PD dementia with Lewy bodies
  • ALS Amytrophic Lateral Sclerosis
  • ALS subcortical white matter disease or demyelinating disease
  • HIV malaria
  • the system or apparatus may be used for assessing the status of brain disease induced brain dysfunction in a subject, wherein the brain disease induced brain dysfunction is related to dementia, such as Alzheimer's disease; Multiple sclerosis (MS); Parkinson's disease (PD); dementia with Lewy bodies (DLB/LDB); Amytrophic Lateral Sclerosis (ALS); subcortical white matter disease or demyelinating disease; HIV; malaria; cerebrovascular disease (VaD); encephalitis; traumatic brain injury (TBI); mild cognitive impairment (MCI); traumatic brain injury (TBI); effects of street drugs; alcohol abuse; or side effects of prescribed drugs and/or pharmaceutical drug treatments, and diseases of other bodily organs such as heart, liver, lung or otherwise.
  • dementia such as Alzheimer's disease; Multiple sclerosis (MS); Parkinson's disease (PD); dementia with Lewy bodies (DLB/LDB); Amytrophic Lateral Sclerosis (ALS); subcortical white matter disease or demyelinating disease; HIV; malaria; cerebrovascular disease (VaD); ence
  • the above described computer program may in some embodiments enable carrying out embodiments of the above described method.
  • Figs. 5a-b show pause time distributions with the pause time on the y-axis (milliseconds), and the individual pauses on the x-axis in chronological order, starting with a first pause time denoted N1.
  • a 17-year old female patient with ADHD has been tested in an non-medicated state (a) and after a treatment with methylphenidate for 1 h (b). Healthy subjects are displayed as solid triangles, and the patient as open circles.
  • the deviation of the distribution of the individual pause times from the range of reference values (solid triangles) are indicative of the extent of the brain dysfunction. From the pause time distribution it is clear that the frequency and length of the pause times are significantly reduced after the medical treatment.
  • the distribution of pause times may indicate critical deviations associated with isolated events.
  • Fig. 6 shows a pause time distribution of a 12 year-old male patient with ADHD and also recent heart surgery. The test is made in connection with medication. A high frequency of pause times with long durations are shown for the patient (open circles) compared to healthy young subjects (solid triangles).
  • Fig. 7 shows a pause time distribution for a 10 year-old patient with diagnosed epilepsy (open circles), compared to healthy subjects in the same age (solid triangles).
  • Fig. 8 shows a pause time distribution for a 81 year-old female patient with diagnosed Alzheimer's decease.
  • the duration of the test was 64.8 seconds in order for the patient to complete the test.
  • a moderate frequency of long pause times were detected (open circles) compared to healthy control subjects around the same age (solid triangles)
  • Vertical lines indicates one standard deviation.
  • a predefined number of individual pause times exceeding a pause time threshold duration may be set.
  • a predefined threshold duration of 1100 ms may be set, which is outside the standard deviation of the reference range (solid triangles).
  • the number of individual pause times exceeding the pause time threshold duration is in Fig. 8 amounting to 6 individual pause times. Accordingly, any threshold below this number of individual pause times would be indicative of a brain dysfunction.
  • the individual pause times not overlapping with the range of reference values may be determined throughout the temporally resolved pause time distribution, to determine the occurrence and/or stage of the brain disease induced brain dysfunction.
  • An array or index may be recorded indicating the occurrence of such deviations in a temporally resolved manner, which may be indicative of certain critical events or parts of a cognitive test performed by a subject, thereby taking into account any variations in the range of reference values determined for the corresponding test.
  • a compromise of the self-paced speed of intrinsic brain processing to open-ended external information may in fact be one of the earliest behavioural consequences of brain dysfunction, which can be characterized by Excessive pause time durations of low frequencies (0.01 - 0.1 Hz) may be evidence for moment-to-moment attentional fluctuations seen for example in Alzheimer's disease.
  • This is a characteristic of the compromise of the self-paced speed of intrinsic brain processing to open-ended external information, which may in fact be one of the earliest behavioural consequences of brain dysfunction, as discussed previously.
  • Fig. 9 shows a pause time distribution for a 74 year-old male patient with diagnosed Alzheimer's decease with a high frequency of long pause times (open circles) compared to healthy control subjects(solid triangles,+/- one standard deviation). From the pause time spectra it is seen that there are relatively small variations in the lengths of the pause time during the test of 138.1 seconds.
  • Fig. 10 shows a pause time distribution of healthy young subjects (solid triangles), young patients with diagnosed ADHD (solid circles in the middle of the figure), and young patients with other diagnosed neurological disabilities (solid circles in the upper part of the figure). Vertical lines within each group indicates +/- one standard deviation. It is seen that the variation differs significantly between the groups of patients, and is largest for the group of patients with other disabilities than ADHD.
  • Fig. 11 is a schematic illustration of an embodiment of the invention, showing a method 5, comprising the below steps 1 to 3. This embodiments make use of the assessment of a recognition time and memory retrieval time and their respective contribution to a pause time duration.
  • Step 1 Assessment is made of recognition time for a stimulus - which is a part of the pause time measured in step 3).
  • a stimulus S is shown for a stimulation time ts (in parts of a second in Fig. 1 ).
  • the stimulus S may be shown repeatedly with increasing time until a threshold time is reliably determined where the subject correctly identifies the presented stimulus. Adjustment is made of the lowest time level to correctly recognise the stimuli. For instance, the adjustment starts at the fastest level (0.1 seconds) and this time of stimulus presentation ts is increased successively until a stable recognition is achieved. Step 3 uses this recognition time threshold ts as a default time, as described below.
  • the subject is able to correctly identify and name the stimulus.
  • This is usually performed or supervised by an examiner, but may also be made software based by the subject alone using a suitable programmed apparatus.
  • the stimulus presentation time can be changed at discrete levels ranging from the lowest level of 0.1 seconds up to the highest level of 1.0 second.
  • the examiner establishes the lowest level for correct identification of the stimulus through the correct verbal response by the subject.
  • the examiner presses the OK-button 49 on the apparatus 4 (see Fig. 4 in PCT/SE2010/050480 ).
  • This OK-signal is then automatically used as the presentation time of the stimulus in Step 3. In this manner a reliable and correct identification of the stimuli is ensured at a minimum presentation time.
  • the component of recognition time for a stimulus - which is a part of the pause time - is reliably determinable.
  • Step 2 Assessment is made of a memory retrieval time tr for a stimulus or probe of working memory - which is a part of the pause time measured in step 3.
  • a sequence or series 21 of a first number of stimuli e.g. four colour stimuli, S1. S2, S3, S4 (see Fig. 2 in PCT/SE2010/050480 ), which are e.g. used as default stimuli, may be presented on a screen of an apparatus (see Fig. 4 in PCT/SE2010/050480 ), over time t.
  • Each first stimuli is visually presented at the set presentation time ts defined in Step 1.
  • the presentation of the stimuli is made in successive order with pre-determined intervals, such as one second intervals, until all stimuli have been shown.
  • the subject is instructed to name the series of first stimuli, in the embodiment the four colour stimuli S1-S4 correctly and in the correct order as soon as all four stimuli have been presented.
  • Retrieval time tr for each individual stimulus is calculated as the mean pause time, i.e. the entire mean pause time divided by the number of presented stimuli - in the example for all four stimuli divided by four.
  • the value for tr-mean is automatically stored, and is used by the apparatus 4 ( Fig. 4 in PCT/SE2010/050480 ) or method to calculate the amount of retrieval time contributing to the individual pause times occurring in Step 3.
  • This procedure may be repeated for a second series of stimuli S5, S6, S7, S8, e.g. four shapes that are different than the shapes of the first series.
  • This step 2 is a test of short-term memory and a measurement value therefor is provided by tr_mean.
  • tr_mean a measurement value therefor is provided by tr_mean.
  • a different number of stimuli may be used.
  • the method comprises repetitively in a sequence present on a display a pre-defined number of different stimuli individually and in an order, each stimuli being presented during a presentation time, and with a presentation pause of pre-defined length in-between the individual presentations.
  • the presentation time may be the pre-defined recognition time determined previously.
  • a plurality of individual pause times is measured, wherein each individual pause time is a pause time until articulation of the subject in each repetition of the sequence starts in the sound signal (or pre-registered speech) for naming the presented stimuli as quickly as possible and in said order.
  • a statistical distribution of the plurality of individual pause times is determined.
  • An apparatus 4 ( Fig. 4 in PCT/SE2010/050480 ) with control unit 720 ( Fig. 6 in PCT/SE2010/050480 ) may be adapted to perform the method in step 3, and also the method in step 1 and 2.
  • Step 3 may be preceded by determination of a recognition time for a stimulus as a first pause time component, and the determination of a memory retrieval time for a stimulus as a second pause time component, as discussed under steps 1 and 2 above.
  • the stimuli may be presented pair wise. The method is described in more detail below.
  • the stimuli are discrete and the presentation time is separated by a pause time interval (presentation pause time).
  • the minimum time (ts) to correctly identify the stimuli is determined by step 1.
  • the presentation time is preferably as large as ts, in order to ensure a reliable recognition of the two random stimuli S1 and S2 by the subject.
  • the presentation pause time is adjustable and e.g. in the range of 0.1 seconds. This time interval of presentation pause can be adjusted, but a default value of e.g. 0,1 seconds is used.
  • the two stimuli S1, S2 e.g. colour and shape
  • This default value is a dynamic feature of the method and may be increased, e.g. for specifically probing a memory component by the present testing.
  • the individual stimuli S1, S2 as well as the order of a pair wise presentation of the stimuli S1, S2 may be randomised (i.e. in the example sometimes a colour appears as the first stimulus S1, sometimes a shape appears first).
  • the subject is required to always name the stimulus presentation in the correct order.
  • the first presented stimulus S1 is to be named first.
  • the subject is required to name the stimuli S1 and S2 as quickly as possible.
  • the speech recording is automatically started at onset of the first stimulus, and the pause time duration from the end of presenting the second stimulus S2 to the first vocal pronunciation (articulation) of the first stimulus by the subject, is analyzed ( Fig.3 in PCT/SE2010/050480 )
  • the measured individual pause time (34) is here defined as the sum of the stimulus recognition time ts (lowest level in milliseconds, obtained in step 1), and the memory retrieval time tr_mean (The mean pause time for the 4 stimuli in step 2.)
  • the sequence may be repeated, and for every repetition of the sequence of stimuli, an individual pause time is measured.
  • the method automatically subtracts the stimulus presentation times and the interstimulus interval from the recorded sound signal. As sound recording is started in the embodiment before the end of presentation of stimulus S2, any recording delays or measurement errors are avoided. The amount of contribution that the memory retrieval time has contributed to the individual pause time durations, is analyzed. Further, the recognition time is analyzed. Each individual pause time duration may be longer than the added recognition time and retrieval time, due to other brain activity components.
  • the signal provides a measure of the individual pause time durations, and components thereof.
  • the apparatus 4 is shown in an embodiment in Figure 4 in PCT/SE2010/05048 . All above described three steps 1-3 may be performed by means of the apparatus 4.
  • the apparatus 4 is preferably a portable hand held apparatus.
  • the apparatus may comprise communication means to communicate diagnostic results obtained in a suitable context.
  • the buttons 44, 46, 48, 49 may be so-called soft-buttons, i.e. visually presented buttons on a touch sensitive display.
  • Step 1 is performed by adjusting the stimulus recognition time by means of scale 45, e.g. showing discrete intervals, for instance ranging between 0.1 to 1.0 seconds.
  • the adjustment is performed by button 44 whereby the presentation time ts of the stimulus can be adjusted upwards (+) and downwards (-).
  • the OK-button 49 is pressed by the examiner/subject and this stimulus presentation time ts is thereby set as default value by the apparatus.
  • Step 2 (Retrieval time probing working memory) is performed in the manner presented above.
  • the sound is registered by means of the microphone 46 and recorded in a memory of the apparatus 4 for further processing.
  • Steps 1 and 2 the subject may press the START-button 48.
  • pair wise stimuli may be presented on the screen according to Step 3.
  • Two stimuli S1, S2 are shown on the screen 42 and turned on and off in successive order, separated by the presentation pause time, e.g. 0.1 sec as the default value.
  • the duration of each stimulus presentation ts is defined in step 1.
  • the onset of sound recording starts at the onset of the first stimulus S1 and stops after the pronunciation of the second stimulus has occurred. Thereafter, a pause is made, e.g. 1 second elapses (can be adjusted if necessary), until the next presentation of a stimulus pair occurs automatically or is started manually. That means, once the START-button 48 is pressed, the test may continue automatically with an adjustable time interval between presentations, until a plurality, e.g. fourty, randomly generated pairs of stimuli S1, S2 have been presented and a plurality of individual pause times is measured for each pairs of stimuli.
  • the presentation sequences runs automatically a pre-defined number of times, e.g. 40 times as default.
  • the apparatus automatically stops presentation of stimuli according to step 3, when this number is reached.
  • the individual sequences may also be presented separately and each separate sequence is thereby started by the examiner/subject by holding down the START-button, which automatically activates the individual sequence.
  • the control unit is adapted to determine a statistical distribution of the plurality of individual pause times, and determine the occurrence and/or stage of brain disease induced brain dysfunction from the statistical distribution.
  • the statistical distribution of the individual pause times may be a chronological distribution.
  • the distribution may be imposed on a range of normal reference or threshold values for a diagnosis.
  • a threshold value may be defined as a number of individual pause times exceeding a threshold duration for a pause time.
  • Non-overlapping pause times of the statistical distribution compared to a range of reference values may be detected for immediate indications of abnormal deviations in a temporally resolved manner.
  • any nutritional supplementations used by the subject which supplementation is aimed to improve the physical and/or mental well-being of that subject.
  • Such supplementations may involve any vitamin supplementation and any supplementation of any polyunsaturated fatty acids aimed to improve the lipid metabolism of the brain of that subject.
  • any pharmaceutical intervention approach aimed at improving the transmission of any neurotransmitter subservient to any mental processes performed by the brain, such as for example any pharmaceutical drug present or developed in the future for the treatment of neurodevelopmental disorders such as ADHD, autism spectrum disorders or dementia disorders.
  • neurodevelopmental disorders such as ADHD, autism spectrum disorders or dementia disorders.
  • to assess the effect on pause time duration by reducing the build-up of toxic by-products within the brain and/or to increase the elimination of toxic waste products of metabolism in the brain, via the blood-brain barrier and/or via the blood-cerebrospinal fluid barriers of the brain.
  • APP amyloid precursor protein
  • Parkinson's disease and Parkinson's dementia which affect any neurotransmitter system in the brain which overlaps with those neurotransmitter systems known to degenerate in Alzheimer's disease, dementia with Lewy bodies (also called Lewy body dementia), and Frontotemporal dementia.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pathology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medical Informatics (AREA)
  • Physics & Mathematics (AREA)
  • Surgery (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Audiology, Speech & Language Pathology (AREA)
  • Psychology (AREA)
  • Neurosurgery (AREA)
  • Physiology (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
EP10186624A 2010-10-05 2010-10-05 Système et procédés pour analyser les durées des temps de pause dans la parole Withdrawn EP2438863A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP10186624A EP2438863A1 (fr) 2010-10-05 2010-10-05 Système et procédés pour analyser les durées des temps de pause dans la parole
PCT/EP2011/067385 WO2012045774A1 (fr) 2010-10-05 2011-10-05 Système et procédés permettant une analyse des durées de temps de pause dans un discours

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10186624A EP2438863A1 (fr) 2010-10-05 2010-10-05 Système et procédés pour analyser les durées des temps de pause dans la parole

Publications (1)

Publication Number Publication Date
EP2438863A1 true EP2438863A1 (fr) 2012-04-11

Family

ID=44043775

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10186624A Withdrawn EP2438863A1 (fr) 2010-10-05 2010-10-05 Système et procédés pour analyser les durées des temps de pause dans la parole

Country Status (2)

Country Link
EP (1) EP2438863A1 (fr)
WO (1) WO2012045774A1 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018086987A1 (fr) * 2016-11-10 2018-05-17 Koninklijke Philips N.V. Procédé et appareil permettant de déterminer une indication d'une déficience cognitive
US10796805B2 (en) 2015-10-08 2020-10-06 Cordio Medical Ltd. Assessment of a pulmonary condition by speech analysis
US10847177B2 (en) 2018-10-11 2020-11-24 Cordio Medical Ltd. Estimating lung volume by speech analysis
US11011188B2 (en) 2019-03-12 2021-05-18 Cordio Medical Ltd. Diagnostic techniques based on speech-sample alignment
US11024327B2 (en) 2019-03-12 2021-06-01 Cordio Medical Ltd. Diagnostic techniques based on speech models
US11291402B2 (en) 2016-11-10 2022-04-05 Koninklijke Philips N.V. Method and apparatus for determining an indication of cognitive impairment
US11417342B2 (en) 2020-06-29 2022-08-16 Cordio Medical Ltd. Synthesizing patient-specific speech models
US11484211B2 (en) 2020-03-03 2022-11-01 Cordio Medical Ltd. Diagnosis of medical conditions using voice recordings and auscultation

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102715890A (zh) * 2012-07-10 2012-10-10 崔德华 一种基于角度辨别筛查诊断早期老年痴呆症的装置

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6350128B1 (en) * 1997-10-29 2002-02-26 Graham Neuhaus Rapid automatized naming method and apparatus
EP1205146A2 (fr) 2000-11-13 2002-05-15 Tokai University Educational System Appareil pour tester la démence ainsi que serveur, client et système à cet effet
WO2003015079A1 (fr) * 2001-08-09 2003-02-20 Voicesense Ltd. Procede et dispositif d'analyse de la parole
US20060194176A1 (en) 2003-07-28 2006-08-31 Takaki Shimura Dementia inspection apparatus dementia inspection server dementia inspection client and dementia inspection system Dementia check device, dementia check server, dementia check client, and dementia check system
WO2009056650A1 (fr) 2007-11-02 2009-05-07 Siegbert Warkentin Système et procédés pour l'évaluation du cerveau vieillissant et de ses dysfonctionnements cérébraux induits par une maladie du cerveau par analyse de la parole
US20100174533A1 (en) * 2009-01-06 2010-07-08 Regents Of The University Of Minnesota Automatic measurement of speech fluency
WO2010128934A1 (fr) * 2009-05-04 2010-11-11 Siegbert Warkentin Appareil et procédé d'aide vocale au diagnostic

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6350128B1 (en) * 1997-10-29 2002-02-26 Graham Neuhaus Rapid automatized naming method and apparatus
EP1205146A2 (fr) 2000-11-13 2002-05-15 Tokai University Educational System Appareil pour tester la démence ainsi que serveur, client et système à cet effet
WO2003015079A1 (fr) * 2001-08-09 2003-02-20 Voicesense Ltd. Procede et dispositif d'analyse de la parole
US20060194176A1 (en) 2003-07-28 2006-08-31 Takaki Shimura Dementia inspection apparatus dementia inspection server dementia inspection client and dementia inspection system Dementia check device, dementia check server, dementia check client, and dementia check system
WO2009056650A1 (fr) 2007-11-02 2009-05-07 Siegbert Warkentin Système et procédés pour l'évaluation du cerveau vieillissant et de ses dysfonctionnements cérébraux induits par une maladie du cerveau par analyse de la parole
US20100174533A1 (en) * 2009-01-06 2010-07-08 Regents Of The University Of Minnesota Automatic measurement of speech fluency
WO2010128934A1 (fr) * 2009-05-04 2010-11-11 Siegbert Warkentin Appareil et procédé d'aide vocale au diagnostic

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CANNIZZARO MICHAEL S ET AL: "Bradyphrenia and bradykinesia both contribute to altered speech in schizophrenia: a quantitative acoustic study.", COGNITIVE AND BEHAVIORAL NEUROLOGY : OFFICIAL JOURNAL OF THE SOCIETY FOR BEHAVIORAL AND COGNITIVE NEUROLOGY DEC 2005 LNKD- PUBMED:16340393, vol. 18, no. 4, December 2005 (2005-12-01), pages 206 - 210, XP008137295, ISSN: 1543-3633 *
VOGEL ADAM P ET AL: "Reliability, stability, and sensitivity to change and impairment in acoustic measures of timing and frequency.", JOURNAL OF VOICE : OFFICIAL JOURNAL OF THE VOICE FOUNDATION MAR 2011 LNKD- PUBMED:20171828, vol. 25, no. 2, March 2011 (2011-03-01), pages 137 - 149, XP008137284, ISSN: 1557-8658 *
WARKENTIN S ET AL: "rCBF pathology in Alzheimer's disease is associated with slow processing speed", NEUROPSYCHOLOGIA, PERGAMON PRESS, OXFORD, GB, vol. 46, no. 5, 1 January 2008 (2008-01-01), pages 1193 - 1200, XP022640891, ISSN: 0028-3932, [retrieved on 20070914], DOI: 10.1016/J.NEUROPSYCHOLOGIA.2007.08.029 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10796805B2 (en) 2015-10-08 2020-10-06 Cordio Medical Ltd. Assessment of a pulmonary condition by speech analysis
WO2018086987A1 (fr) * 2016-11-10 2018-05-17 Koninklijke Philips N.V. Procédé et appareil permettant de déterminer une indication d'une déficience cognitive
US11291402B2 (en) 2016-11-10 2022-04-05 Koninklijke Philips N.V. Method and apparatus for determining an indication of cognitive impairment
US10847177B2 (en) 2018-10-11 2020-11-24 Cordio Medical Ltd. Estimating lung volume by speech analysis
US11011188B2 (en) 2019-03-12 2021-05-18 Cordio Medical Ltd. Diagnostic techniques based on speech-sample alignment
US11024327B2 (en) 2019-03-12 2021-06-01 Cordio Medical Ltd. Diagnostic techniques based on speech models
US11484211B2 (en) 2020-03-03 2022-11-01 Cordio Medical Ltd. Diagnosis of medical conditions using voice recordings and auscultation
US11417342B2 (en) 2020-06-29 2022-08-16 Cordio Medical Ltd. Synthesizing patient-specific speech models

Also Published As

Publication number Publication date
WO2012045774A1 (fr) 2012-04-12

Similar Documents

Publication Publication Date Title
EP2438863A1 (fr) Système et procédés pour analyser les durées des temps de pause dans la parole
Levendowski et al. The accuracy, night-to-night variability, and stability of frontopolar sleep electroencephalography biomarkers
König et al. Automatic speech analysis for the assessment of patients with predementia and Alzheimer's disease
Mundt et al. Voice acoustic measures of depression severity and treatment response collected via interactive voice response (IVR) technology
Russo et al. Brainstem responses to speech syllables
US10383540B2 (en) Cognitive function evaluation apparatus, method, system and program
US20100298649A1 (en) System and methods for assessment of the aging brain and its brain disease induced brain dysfunctions by speech analysis
Rabinowitz et al. Association between finger tapping, attention, memory, and cognitive diagnosis in elderly patients
TWI666633B (zh) Cognitive function evaluation device, cognitive function evaluation system, cognitive function evaluation method and program
Alpert et al. A comparison of clinical ratings with vocal acoustic measures of flat affect and alogia
Francis et al. Listener characteristics differentially affect self-reported and physiological measures of effort associated with two challenging listening conditions
WO2019188405A1 (fr) Dispositif d'évaluation de fonction cognitive, système d'évaluation de fonction cognitive, procédé d'évaluation de fonction cognitive et programme
Morein-Zamir et al. Novel measures of response performance and inhibition in children with ADHD
Järvinen et al. Relations between social-perceptual ability in multi-and unisensory contexts, autonomic reactivity, and social functioning in individuals with Williams syndrome
Kemp et al. Effects of task difficulty on neural processes underlying semantics: An event-related potentials study
Jacquemot et al. Improving language evaluation in neurological disorders: The French Core Assessment of Language Processing (CALAP).
Bialas et al. Pain in tones–Is it possible to hear the pain quality? A pilot trial
Zhishuai et al. Processing of emotional faces in congenital amusia: An emotional music priming event-related potential study
Murphy Listening Fatigue in College Students
US20120109005A1 (en) Apparatus and method for voice based diagnostic support
Kalsy et al. The assessment of dementia in people with intellectual disabilities: key assessment instruments
Freestone et al. The Effects of Yoga Breathing Before Motor Speech Practice in Acquired Apraxia of Speech: An n-of-1 Trial
Lundervold et al. Alternate forms reliability of the Behavioral Relaxation Scale: Preliminary results.
Barroso Application game and low-cost BCI measurement of electrical scalp activity as an additional tool to test children with ADHD
Poole Quantification of motor speech in primary progressive aphasia and frontotemporal dementia

Legal Events

Date Code Title Description
AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20121012